Aclaris Q4 loss narrows, but misses analysts' expectations

Overview

• Biopharmaceutical firm Aclaris Q4 revenue and net loss missed analyst expectations

• Company reported a net loss of $19.8 mln for Q4 2025, narrower than year-ago

• Aclaris maintains strong cash position to fund operations into second half of 2028

Outlook

• Aclaris expects top line results from Phase 1b trials of ATI-052 in H2 2026

• Company plans to file IND for ATI-9494 in H2 2026

• Aclaris anticipates Phase 2 trial results for bosakitug in AD in H2 2026

Result Drivers

• ATI-052 TRIAL RESULTS - Positive interim Phase 1a results for ATI-052 showed strong safety and tolerability, supporting further clinical advancement

• PHASE 1B TRIALS INITIATED - Aclaris initiated Phase 1b proof-of-concept trials for ATI-052 in atopic dermatitis and asthma

• HAIR REGROWTH POTENTIAL - ATI-2138 showed potential best-in-class hair regrowth in a murine model of alopecia areata

Company press release: ID:nGNX8wXC26

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Aclaris Therapeutics Inc is $7.00, about 111.5% above its February 25 closing price of $3.31

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)